image: The 48th Annual UNC Lineberger Scientific Symposium is a day-and-a-half meeting exploring advances across the cancer research continuum—from molecular discovery to clinical application to population impact—that are improving cancer outcomes. The meeting features 16 talks by leaders in cancer research that bridge basic, translational and population sciences.
Credit: UNC Lineberger Comprehensive Cancer Center
Join leading cancer researchers, clinicians, and population scientists for the 48th Annual UNC Lineberger Scientific Symposium, a day-and-a-half meeting in Chapel Hill, North Carolina, exploring advances across the cancer research continuum—from molecular discovery to clinical application to population impact—that are improving cancer outcomes.
This year’s symposium commemorates the 50th anniversary of UNC Lineberger’s designation as a National Cancer Institute-designated cancer center.
It will feature 16 talks by leaders in cancer research that bridge basic, translational and population sciences.
The meeting will be livestreamed and is free, though registration is required.
Featured Speakers and Topics
Lewis Cantley, PhD – Dana-Farber Cancer Institute
Protein kinase specificity and cellular regulation in cancer
Melissa B. Davis, PhD – Morehouse School of Medicine
Genomic inequities and population-level cancer disparities
Julian Downward, PhD – Francis Crick Institute
RAS oncogenic signaling and immune evasion strategies
Tony Hunter, PhD – Salk Institute
Four decades of tyrosine phosphorylation and its therapeutic impact
William G. Kaelin Jr., MD – Dana-Farber Cancer Institute
The VHL tumor suppressor and targeting the “undruggable”
Edison T. Liu, MD – The Jackson Laboratory
Genomic biology of triple-negative breast cancer
Elaine Mardis, PhD – The Ohio State University
Genomic diversity and treatment outcomes in Black AML patients
W. Kimryn Rathmell, MD, PhD – The Ohio State University
Lineberger’s past and future: a model for comprehensive cancer care
Kurt M. Ribisl, PhD – UNC Gillings School of Global Public Health
Cancer prevention through interdisciplinary public health strategies
Arlene Sharpe, MD, PhD – Harvard Medical School
CRISPR-powered discovery of immunotherapy targets
Kevan Shokat, PhD – UC San Francisco
Breaking the barrier: drugging K-Ras
Melissa Troester, PhD – UNC Gillings School of Global Public Health
Multimodal data to optimize breast cancer outcomes
Stephanie B. Wheeler, PhD, MPH – UNC Gillings School of Global Public Health
Collaborative frameworks for improving cancer care in NC
Kwok-Kin Wong, MD, PhD – NYU Langone Health
Targeting lung squamous cell carcinoma
Yue Xiong, PhD – Cullgen Inc.
Targeted protein degradation as a therapeutic platform